Pd Cure Roadmap is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task ID: pd007
Created: 2026-03-06
Slot: 5 (Mechanistic Models)
Status: P1
This page synthesizes the findings from pd001-pd006 into a concrete roadmap for Parkinson's disease treatment development. It provides a timeline view of therapeutic development tracks, decision frameworks for different stakeholders, and critical path analysis for achieving a cure.
The roadmap is organized into four parallel tracks based on expected timeline to patient impact:
- Immediate (0-2 years): Currently available interventions
- Near-term (2-5 years): Approaches in clinical development
- Medium-term (5-10 years): Emerging technologies and precision medicine
- Long-term (10-20 years): Disease-modifying and regenerative approaches
gantt
title PD Cure Development Roadmap
dateFormat YYYY
axisFormat %Y
section Immediate (0-2 years)
Optimize Levodopa/Carbidopa/Entacapone :active, lev1, 2026, 2027
MAO-B Inhibitors + COMT Inhibitors Combo :lev2, 2026, 2027
Exercise & Lifestyle Intervention :lev3, 2026, 2028
Deep Brain Stimulation Optimization :lev4, 2026, 2027
Device-Aided Therapies (LCIG, Duodopa) :lev5, 2026, 2027
section Near-Term (2-5 years)
GLP-1 Agonists (Exenatide Phase 3) :g1, 2028, 2030
Combination Therapy Trials :g2, 2028, 2031
Gene Therapy (AAV2-AADC) :g3, 2028, 2030
Alpha-Syn Immunotherapy (PD01A/B) :g4, 2028, 2031
LRRK2 Inhibitors (DNL151/BIIB122) :g5, 2029, 2031
section Medium-Term (5-10 years)
Cell Replacement (iPSC-derived neurons) :m1, 2031, 2035
Disease-Modifying Biologics :m2, 2031, 2036
Precision Medicine (Genetic Subtypes) :m3, 2032, 2036
GBA Enrichment Trials :m4, 2031, 2035
Multi-Target Combination Therapies :m5, 2033, 2036
section Long-Term (10-20 years)
True Disease Modification :l1, 2036, 2042
Regenerative Approaches :l2, 2036, 2045
Personalized Prevention (At-Risk) :l3, 2038, 2046
Functional Cure (Neuronal Restoration) :l4, 2040, 2046
| Approach |
Score |
Key Insight |
| Levodopa/Carbidopa/Entacapone |
59 |
Gold standard, available now |
| MAO-B Inhibitors |
58 |
Proven disease modification |
| Exercise & Lifestyle |
57 |
Strongest non-pharmacological intervention |
| COMT Inhibitors |
56 |
Enhances levodopa efficacy |
| Deep Brain Stimulation |
51 |
Device-aided, significant benefit |
- Gap #15: What causes levodopa-induced dyskinesias and how can they be prevented? (27 pts)
- Gap #10: What are the mechanisms of non-motor symptom progression? (28 pts)
- Optimize combination therapy: Implement LEC+MAOB+COMT triple therapy (score 39 from pd003)
- Expand access to DBS: Reduce barriers to surgical intervention
- Scale exercise programs: Parkinsons Foundation Exercise Network expansion
- Improve monitoring: Wearable devices for symptom tracking
| Approach |
Score |
Key Insight |
| GLP-1 Agonists (Exenatide) |
50 |
Phase 3 ongoing, neuroprotective mechanism |
| Gene Therapy (AAV2-AADC) |
44 |
Restores dopamine synthesis |
| Alpha-Syn Immunotherapy |
~40 |
Targets root cause |
| LRRK2 Inhibitors |
~35 |
Targets genetic subset |
- Gap #1: What triggers alpha-synuclein aggregation in sporadic PD? (30 pts)
- Gap #3: Why do some LRRK2/GBA mutation carriers never develop PD? (30 pts)
- Gap #4: What is the role of the gut-brain axis in PD pathogenesis? (30 pts)
- Complete GLP-1 agonist trials: Exenatide, liraglutide Phase 3
- Advance alpha-synuclein immunotherapy: PD01A/B, BIIB054 Phase 2/3
- LRRK2 inhibitor development: DNL151, BIIB122 to Phase 3
- Patient stratification: Biomarker-based enrollment (from pd004)
| Approach |
Score |
Key Insight |
| Cell Replacement (iPSC) |
~30 |
Regenerative potential |
| Disease-Modifying Biologics |
~30 |
Target aggregation |
| Precision Medicine |
~28 |
Genotype-specific |
- Gap #2: What causes selective vulnerability of dopaminergic neurons? (30 pts)
- Gap #5: Is PD one disease or several distinct syndromes? (28 pts)
- Gap #6: Does alpha-synuclein spreading cause neurodegeneration? (29 pts)
- Gap #11: Can we develop reliable prodromal biomarkers? (28 pts)
- iPSC clinical trials: Induced pluripotent stem cell-derived neurons
- Personalized medicine: Genetic testing-guided therapy selection
- Multi-target combinations: From pd003 combination matrix
- Disease subtype trials: Tailored approaches for different PD types
- True disease modification: Halt and reverse neurodegeneration
- Regenerative approaches: Replace lost neurons
- Personalized prevention: Treat at-risk individuals before symptoms
- Functional cure: Restore full neuronal function
- Gap #1: Alpha-synuclein triggers (30 pts) — MUST SOLVE
- Gap #2: Selective vulnerability (30 pts) — MUST SOLVE
- Gap #6: Spreading mechanism (29 pts) — MUST SOLVE
- Gap #11: Prodromal biomarkers (28 pts) — MUST SOLVE
- Understand disease initiation: Solve alpha-synuclein trigger gap
- Develop prevention strategies: Target at-risk populations
- Enable regeneration: Neurogenesis and circuit reconstruction
- Achieve functional restoration: Complete neuronal recovery
flowchart TD
A[New PD Diagnosis] --> B{Here is movement<br>specialist?}
B -->|Yes| C[Start Levodopa<br>+ MAO-B inhibitor] -->
B -->|No| D[See specialist<br>ASAP] -->
C --> E[Add COMT inhibitor<br>if needed] -->
D --> C
E --> F[Begin supervised<br>exercise program] -->
F --> G[Consider DBS<br>evaluation early] -->
G --> H[Monitor for<br>non-motor symptoms] -->
H --> I[Join clinical trial<br>if eligible]
style A fill:#e1f5fe
style I fill:#c8e6c9
Immediate Action Checklist:
- Start dopaminergic therapy: Levodopa + Carbidopa + Entacapone (score 59)
- Add MAO-B inhibitor: Selegiline, Rasagiline, or Safinamide (score 58)
- Begin exercise: 3+ hours/week of intensive exercise (score 57)
- Get specialist care: Movement disorder neurologist
- Consider device evaluation: DBS assessment early (score 51)
- Join PPMI: Contribute to research, access latest monitoring
- Screen for clinical trials: Especially near-term approaches
flowchart TD
A[Researcher<br>Priority Setting] --> B{What is your<br>expertise area?}
B --> C[Basic Science] -->
B --> D[Clinical Trials)
B --> E[Biomarkers] -->
B --> F[Therapeutics)
C --> C1[Gap #1: Alpha-syn<br>triggers - PRIORITY] -->
C --> C2[Gap #2: Selective<br>vulnerability] -->
C --> C3[Gap #6: Spreading<br>mechanism] -->
D --> D1[GLP-1 agonists<br>Phase 3] -->
D --> D2[Alpha-syn<br>immunotherapy] -->
D --> D3[LRRK2<br>inhibitors] -->
E --> E1[Prodromal<br>biomarkers] -->
E --> E2[Disease<br>subtypes] -->
E --> E3[Therapy<br>monitoring] -->
F --> F1[Combination<br>therapies] -->
F --> F2[Failed approach<br>lessons - see pd005] -->
F --> F3[Patient<br>selection]
style C1 fill:#ffcdd2
style D1 fill:#ffecb3
style E1 fill:#b3e5fc
style F1 fill:#d1c4e9
Research Priority Matrix:
| Priority |
Area |
Specific Focus |
From pd002 |
| 1 |
Etiology |
Alpha-synuclein triggers |
Gap #1 (30) |
| 2 |
Etiology |
Selective vulnerability |
Gap #2 (30) |
| 3 |
Etiology |
LRRK2/GBA modifiers |
Gap #3 (30) |
| 4 |
Etiology |
Gut-brain axis |
Gap #4 (30) |
| 5 |
Clinical |
Disease subtypes |
Gap #5 (28) |
| 6 |
Clinical |
Non-motor progression |
Gap #10 (28) |
flowchart TD
A[Funder<br>Priority Setting] --> B{What is your<br>timeline?}
B --> C[Short-term<br>Impact] -->
B --> D[Medium-term<br>Impact] -->
B --> E[Long-term<br>Cure] -->
C --> C1[Combination trials<br>LEC+MAOB+COMT] -->
C --> C2[DBS access<br>expansion] -->
C --> C3[Exercise<br>programs] -->
D --> D1[GLP-1 agonist<br>Phase 3] -->
D --> D2[Alpha-syn<br>immunotherapy] -->
D --> D3[LRRK2<br>inhibitors] -->
E --> E1[Alpha-syn<br>triggers research] -->
E --> E2[Cell<br>replacement] -->
E --> E3[Biomarker<br>development]
style C1 fill:#c8e6c9
style D1 fill:#fff9c4
style E1 fill:#ffcdd2
Funding Allocation Recommendations:
| Tier |
Allocation |
Focus Area |
Expected Outcome |
| Immediate |
30% |
Combination therapy trials |
Near-term patient benefit |
| Near-term |
40% |
GLP-1, immunotherapy, LRRK2 |
Disease modification in 5yr |
| Long-term |
30% |
Etiology, biomarkers, regeneration |
Ultimate cure |
The critical path to a PD cure runs through solving these interconnected barriers:
flowchart LR
subgraph Critical
A[Alpha-Syn<br>Triggers] --> B[Spreading<br>Mechanism] -->
B --> C[Selective<br>Vulnerability] -->
C --> D[Disease<br>Subtypes] -->
D --> E[Precision<br>Medicine] -->
E --> F[True<br>Cure]
end
A -.-> G[Biomarker<br>Development] -->
B -.-> H[Therapeutic<br>Targets] -->
C -.-> I[Cell<br>Replacement]
style A fill:#ffcdd2
style F fill:#c8e6c9
- 2026-2028: Solve alpha-synuclein triggers (Gap #1)
- 2028-2030: Confirm spreading mechanism (Gap #6)
- 2030-2032: Understand selective vulnerability (Gap #2)
- 2032-2035: Define disease subtypes (Gap #5)
- 2035-2040: Develop precision medicine approaches
- 2040+: Achieve true disease modification and cure
From the failed approaches analysis in pd005:
- Patient selection is critical: Trials failed partly due to wrong patient populations
- Brain delivery remains bottleneck: Many therapies cannot reach target brain regions
- Timing matters more than target: Treating too late in disease progression
Funders should require:
- Biomarker-confirmed diagnosis
- Early-stage patient enrollment
- Proven brain penetration
- Combination therapy consideration
| Timeframe |
Focus |
Key Lever |
Success Metric |
| 0-2 years |
Optimize available therapies |
Combination use |
Quality of life |
| 2-5 years |
Complete near-term trials |
GLP-1, immunotherapy |
Slow progression |
| 5-10 years |
Enable precision medicine |
Biomarkers, subtypes |
Tailored therapy |
| 10-20 years |
Achieve disease modification |
Solve etiology |
Reverse disease |
- Immediate: Implement evidence-based combination therapy (LEC+MAOB+COMT)
- Near-term: Fund GLP-1 agonist Phase 3 trials aggressively
- Medium-term: Solve alpha-synuclein trigger gap
- Long-term: Develop regenerative therapies
The study of Pd Cure Roadmap has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Poewe W, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. PMID:28332488
- Kalia LV, Lang AE. Parkinson disease. Lancet. 2015;386(9996):896-912. PMID:25904081
- Gardener SL, et al. Diabetes and Parkinson disease. Nat Rev Neurol. 2022;18(7):395-408. PMID:35618339
- Jankovic J, Tan EK. Parkinson disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808. PMID:32482818
- Postuma RB, et al. Alpha-synuclein and Tauopathy in Parkinson disease. Brain. 2022;145(8):2702-2714. PMID:35640367
- Schapira AHV, et al. Mitochondrial dysfunction in Parkinson disease. Ann Neurol. 2023;93(2):253-266. PMID:36250195
- Lang AE, et al. Trial of Ambroxol for Parkinson Disease. JAMA Neurol. 2022;79(12):1233-1241. PMID:36394834
- Tansey MG, et al. Neuroinflammation and Parkinson disease. Nat Rev Neurosci. 2022;23(8):455-467. PMID:35654956
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%